Skip to main content

DC-based immunotherapy to treat Malignant Mesothelioma

Objective

Asbestos is one of the major occupational carcinogens. The European Union has an extensive history of protecting workers and consumers against asbestos and even adopted a resolution 2012/2065(INI) ‘on asbestos related occupational health threats and prospects for abolishing all existing asbestos’ last year. Although asbestos is banned, it is still massively present in the built environment. Millions of workers & consumers in the EU were, and still are, for many years exposed to asbestos fibres, despite all measures.

Inhalation of even very low quantities of asbestos fibres tremendously increases the risk of developing Malignant Mesothelioma (MM). The IARC reported 8.100 MM deaths in 2010 in the EU. Despite all EU actions, MM incidence is still increasing. MM is a highly fatal disease with a poor median survival time from first signs of illness to death around 12 months despite aggressive treatments. To date there is no curative therapy for MM. MM is considered as an extremely therapy-resistant disease. Chemotherapy consisting of a combination of pemetrexed and cisplatin is considered standard of care with a median survival increase of 3 months (9-12 months).

The department of pulmonary diseases of the Erasmus MC, Rotterdam, The Netherlands, in collaboration with international partners, have developed a promising personalised immunotherapy for MM with very limited adverse effects. The first clinical results show a considerably prolonged average survival with limited adverse events (24 months, twice as long).

The EMA and the FDA granted this therapy Orphan Designation: autologous dendritic cells pulsed with allogeneic tumour cell lysate for the treatment of malignant mesothelioma (EU: 16 January 2014 - EU/3/13/1229; FDA – US: 06 May 2014).

The objective for the project is to deliver the scientific & registration package for market approval by the EMA of a novel immuno therapeutic approach to treat MM. This includes the execution of a phase II/III clinical trial.

Field of science

  • /medical and health sciences/basic medicine/immunology/immunotherapy
  • /medical and health sciences/clinical medicine/cancer

Call for proposal

H2020-PHC-2015-two-stage
See other projects for this call

Funding Scheme

RIA - Research and Innovation action

Coordinator

ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
Address
Dr Molewaterplein 40
3015 GD Rotterdam
Netherlands
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 2 375 146,94

Participants (7)

UNIVERSITA POLITECNICA DELLE MARCHE
Italy
EU contribution
€ 669 452,73
Address
Piazza Roma 22
60121 Ancona
Activity type
Higher or Secondary Education Establishments
STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Netherlands
EU contribution
€ 669 451,91
Address
Plesmanlaan 121
1066 CX Amsterdam
Activity type
Research Organisations
UNIVERSITAIR ZIEKENHUIS ANTWERPEN
Belgium
EU contribution
€ 668 874,95
Address
Drie Eikenstraat 655
2650 Edegem
Activity type
Research Organisations
UNIVERSITY OF LEICESTER
United Kingdom
EU contribution
€ 669 215,63
Address
University Road
LE1 7RH Leicester
Activity type
Higher or Secondary Education Establishments
CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE
France
EU contribution
€ 659 822,84
Address
Avenue Oscar Lambret 2
59037 Lille
Activity type
Higher or Secondary Education Establishments
EUROPEAN CANCER PATIENT COALITION
Belgium
EU contribution
€ 23 000
Address
Rue Montoyer 40
1000 Bruxelles
Activity type
Other
AMPHERA BV
Netherlands
EU contribution
€ 48 000
Address
Onderwijsboulevard 225
5223 DE Den Bosch
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)